These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35029310)

  • 1. Innovative vaccine approaches-a Keystone Symposia report.
    Cable J; Rappuoli R; Klemm EJ; Kang G; Mutreja A; Wright GJ; Pizza M; Castro SA; Hoffmann JP; Alter G; Carfi A; Pollard AJ; Krammer F; Gupta RK; Wagner CE; Machado V; Modjarrad K; Corey L; B Gilbert P; Dougan G; Lurie N; Bjorkman PJ; Chiu C; Nemes E; Gordon SB; Steer AC; Rudel T; Blish CA; Sandberg JT; Brennan K; Klugman KP; Stuart LM; Madhi SA; Karp CL
    Ann N Y Acad Sci; 2022 May; 1511(1):59-86. PubMed ID: 35029310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in vaccine development for infectious diseases-a Keystone Symposia report.
    Cable J; Graham BS; Koup RA; Seder RA; Karikó K; Pardi N; Barouch DH; Sharma B; Rauch S; Nachbagauer R; Forsell MNE; Schotsaert M; Ellebedy AH; Loré K; Irvine DJ; Pilkington E; Tahtinen S; Thompson EA; Feraoun Y; King NP; Saunders K; Alter G; Moin SM; Sliepen K; Karlsson Hedestam GB; Wardemann H; Pulendran B; Doria-Rose NA; He WT; Juno JA; Ataca S; Wheatley AK; McLellan JS; Walker LM; Lederhofer J; Lindesmith LC; Wille H; Hotez PJ; Bekker LG
    Ann N Y Acad Sci; 2023 Jun; 1524(1):65-86. PubMed ID: 37020354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Cernuschi T; Malvolti S; Hall S; Debruyne L; Bak Pedersen H; Rees H; Cooke E
    Vaccine; 2024 Apr; 42 Suppl 1(Suppl 1):S64-S72. PubMed ID: 38103962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.
    Kumar Suri R; Hayman B; Prasad SD; Makhoana M; Tippoo P
    Vaccine; 2022 Jun; 40(26):3495-3505. PubMed ID: 35577632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Ford A; Hwang A; Mo AX; Baqar S; Touchette N; Deal C; King D; Earle K; Giersing B; Dull P; Hall BF
    Vaccine; 2023 Mar; 41(11):1799-1807. PubMed ID: 36803897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors, enablers and challenges for COVID-19 vaccine development.
    Excler JL; Saville M; Privor-Dumm L; Gilbert S; Hotez PJ; Thompson D; Abdool-Karim S; Kim JH
    BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37277195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development and approval of COVID-19 vaccines.
    Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
    Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity.
    Innis BL; Berlanda Scorza F; Blum JS; Jain VK; Older Aguilar A; Post DJ; Roberts PC; Wairagkar N; White J; Bresee J
    Vaccine; 2019 Aug; 37(35):4823-4829. PubMed ID: 31362819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving pandemic preparedness through better, faster influenza vaccines.
    Newland M; Durham D; Asher J; Treanor JJ; Seals J; Donis RO; Johnson RA
    Expert Rev Vaccines; 2021 Mar; 20(3):235-242. PubMed ID: 33576708
    [No Abstract]   [Full Text] [Related]  

  • 10. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
    Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
    Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risky business: COVAX and the financialization of global vaccine equity.
    Stein F
    Global Health; 2021 Sep; 17(1):112. PubMed ID: 34544439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.
    Aripov T; Wikler D; Asadov D; Tulekov Z; Murzabekova T; Munir KM
    BMC Med Ethics; 2022 Mar; 23(1):21. PubMed ID: 35264173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar T; Raut D; Bhatt LK
    Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine equity: Past, present, and future.
    van der Graaf R; Browne JL; Baidjoe AY
    Cell Rep Med; 2022 Mar; 3(3):100551. PubMed ID: 35474741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries.
    Parray AA; Yadav UN; Das A; Ali AM; Mollick S; Saha S; Mistry SK
    Glob Public Health; 2022 Apr; 17(4):614-621. PubMed ID: 35050840
    [No Abstract]   [Full Text] [Related]  

  • 16. Silver lining of COVID-19: Heightened global interest in pneumococcal and influenza vaccines, an infodemiology study.
    Paguio JA; Yao JS; Dee EC
    Vaccine; 2020 Jul; 38(34):5430-5435. PubMed ID: 32620371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving path-dependent equity for global COVID-19 vaccine allocation.
    So AD; Woo J
    Med; 2021 Apr; 2(4):373-377. PubMed ID: 33758829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases.
    Mao W; Zimmerman A; Urli Hodges E; Ortiz E; Dods G; Taylor A; Udayakumar K
    BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37696544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.